14 August 2015 | News | By BioSpectrum Bureau
CrystalGenomics partners with Dong-A for Acelex commercialization
Dong-A ST will secure exclusive rights in Korea to sell and market Acelex
Singapore: Korea based CrystalGenomics has signed a sales and marketing agreement with Dong-A ST for the commercialization of Acelex (polmacoxib) in Korea.
Acelex is a tissue-selective, once-a-day osteoarthritis drug with a novel mode of action that specifically targets affected joints to relieve pain and restore mobility, while simultaneously preserving the integrity and safety of the gastrointestinal and cardiovascular systems.
Under the terms of the agreement, Dong-A ST will secure exclusive rights in Korea to sell and market Acelex, 2mg capsule, a novel NSAID developed by CrystalGenomics for the treatment of osteoarthritis.
Dong-A ST, one of the largest South Korean pharmaceutical companies, manufactures and markets pharmaceutical products and medical devices worldwide in various therapeutic areas including gastroenterology, urology, oncology, cardiology and orthopedics.
Dr Joong Myung Cho, chairman and CEO, CrystalGenomics, said, "We are quite pleased with this partnership as Dong-A ST is one of the most established pharmaceutical companies in Korea. Additionally, Dong-A ST's solid sales and marketing infrastructure makes them an ideal commercial partner for us in Korea."